Stifel Nicolaus analyst Suthan Sukumar maintained a Buy rating on Kinaxis Inc today and set a price target of C$245.00. According to TipRanks, Sukumar is an analyst with an average return of -3.6% and ...
10hon MSN
Vistagen targets NDA submission for fasedienol in mid-2026 as PALISADE-3 study nears data readout
Q2 2026 Management View President and CEO Shawn Singh announced "another major milestone in our PALISADE program. The last patient completed the randomized double-blind portion of our PALISADE-3 Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback